About
Immuno-Oncology
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (28)
View allTotal Trials
28
As Lead Sponsor
27
As Collaborator
1
Total Enrollment
4,826
By Phase
PHASE3: 6PHASE1/PHASE2: 4PHASE2: 3PHASE1: 14
By Status
COMPLETED: 20ACTIVE_NOT_RECRUITING: 3RECRUITING: 2NOT_YET_RECRUITING: 1UNKNOWN: 1TERMINATED: 1
Clinical Trials Pipeline28 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT05700448Lead Sponsor
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
PHASE3Not yet recruiting
150 participants
Started: Dec 31, 2025 · Completed: Jun 30, 2029
NCT06741644Lead Sponsor
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
660 participants
Started: Feb 24, 2025 · Completed: Jan 31, 2028
NCT05381753Lead Sponsor
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
N/ACompleted
61 participants
Started: Aug 29, 2022 · Completed: Sep 30, 2024
NCT05297890Lead Sponsor
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
PHASE2Active, not recruiting
70 participants
Started: May 27, 2022 · Completed: Nov 30, 2025
NCT05279300Lead Sponsor
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
PHASE1Recruiting
480 participants
Started: Mar 28, 2022 · Completed: Dec 31, 2027
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...